Mealey's (April 23, 2020, 10:09 AM EDT) -- WASHINGTON, D.C. — A panel of the Federal Circuit U.S. Court of Appeals on April 21 upheld findings by a Delaware federal judge that the portion of a patent extended under the patent term restoration provisions of the Hatch-Waxman Act, 35 U.S.C. § 156 (2018), is not infringed by a proposed twice-daily monomethyl fumarate (MMF) pill (Biogen International GmbH v. Banner Life Sciences LLC, No. 20-1373, Fed. Cir., 2020 U.S. App. LEXIS 12691)....